Loading company…
Oncorena is a Swedish biopharmaceutical company developing ONC175 for metastatic renal cancer, now in clinical trials.
Oncorena develops investigational treatments for metastatic renal cancer, with its primary product ONC175, a synthetic formulation of orellanine given by intravenous infusion and currently in clinical trials. Founded in 2011 and headquartered in Helsingborg, Sweden, the company raised SEK 66 million in December 2021 from investors including HealthCap, Fåhraeus Startup and Growth, and Linc AB. It is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in